|
1.
|
Simon GR, Sharma S, Cantor A, et al: ERCC
1 expression is a predictor of survival in resected patients with
non-small cell lung cancer. Chest. 127:978–983. 2005.
|
|
2.
|
Cobo M, Isla D, Massuti B, et al:
Customizing cisplatin based on quantitative excision repair
cross-complementing 1 mRNA expression: a phase III trial in
non-small cell lung cancer. J Clin Oncol. 25:2747–2754. 2007.
|
|
3.
|
Quinn JE, Kennedy RD, Mullan PB, Gilmore
PM, Carty M, Johnston PG and Harkin DP: BRCA1 functions as a
differential modulator of chemotherapy-induced apoptosis. Cancer
Res. 63:6221–6228. 2003.
|
|
4.
|
Taron M, Rosell R, Felip E, Mendez P,
Souglakos J, Ronco MS, Queralt C, Majo J, Sanchez JM, Sanchez JJ
and Maestre J: BRCA1 mRNA expression levels as an indicator of
chemoresistance in lung cancer. Hum Mol Genet. 13:2443–2449.
2004.
|
|
5.
|
Hotta K, Kiura K, Toyooka S, et al:
Clinical significance of epidermal growth factor receptor gene
mutations on treatment outcome after first-line cytotoxic
chemotherapy in Japanese patients with non-small cell lung cancer.
J Thorac Oncol. 2:632–637. 2007.
|
|
6.
|
Gandara DR, Grimminger P, Mack PC, et al:
Association of epidermal growth factor receptor activating
mutations with low ERCC1 gene expression in non-small cell lung
cancer. J Thorac Oncol. 5:1933–1938. 2010.
|
|
7.
|
Tian SW, Li H, Xie L, et al: The
associated analysis of ERCC1 gene polymorphism in regulatory region
and mRNA Q-PCR expression. Chin Clin Oncol. 12:1073–1076. 2009.
|
|
8.
|
Reed E: ERCC1 and clinical resistance to
platinum-based therapy. Clin Cancer Res. 11:6100–6102. 2005.
|
|
9.
|
Rosell R, Danenberg KD, Alberola V, et al:
Ribonucleotide reductase messenger RNA expression and survival in
gemcitabine/cisplatin-treated advanced non-small cell lung cancer
patients. Clin Cancer Res. 10:1318–1325. 2004.
|
|
10.
|
Lord RV, Brabender J, Gandara D, et al:
Low ERCC1 expression correlates with prolonged survival after
cisplatin plus gemcitabine chemotherapy in non-small cell lung
cancer. Clin Cancer Res. 8:2286–2291. 2002.
|
|
11.
|
Shan L, Han ZG, Liu L, et al: ERCC1 and
BRCA1 expressions in advanced non-small cell lung cancer and their
relationship with cisplatin resistance. Tumor. 29:571–574. 2009.(In
Chinese).
|
|
12.
|
Rosell R, Cecere F, Santarpia M, et al:
Predicting the outcome of chemotherapy for lung cancer. Curr Opin
Pharmacol. 6:323–331. 2006.
|
|
13.
|
Mullan PB, Quinn JE and Harkin DP: The
role of BRCA1 in transcriptional regulation and cell cycle control.
Oncogene. 25:5854–5863. 2006.
|
|
14.
|
Kennedy RD, Quinn JE, Mullan PB, et al:
The role of BRCA1 in the cellular response to chemotherapy. J Natl
Cancer Inst. 96:1659–1668. 2004.
|
|
15.
|
Jorissen RN, Walker F, Pouliot N, et al:
Epidermal growth factor receptor: mechanisms of activation and
signaling. Exp Cell Res. 284:31–53. 2003.
|
|
16.
|
Mok TS, Wu YL, Thongprasert S, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N
Engl J Med. 361:947–957. 2009.
|
|
17.
|
Wang JR, Zhang SP, Lai RS, et al: Intron 1
(CA) n dinucleotide repeat polymorphism and mutations of epidermal
growth factor receptor and responsiveness of molecular targeted
therapy in lung cancer. Mod Pathol. 17:2113–2117. 2009.
|
|
18.
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004.
|
|
19.
|
Bell DW, Lynch TJ, Haserlat SM, et al:
Epidermal growth factor receptor mutations and gene amplification
in non-small cell lung cancer: molecular analysis of the
IDEAL/INTACT gefitinib trials. J Clin Oncol. 23:8081–8092.
2005.
|
|
20.
|
Wu JU, Yub CJ, Shih JY, et al: Influence
of first-line chemotherapy and EGFR mutations on second-line
gefitinib in advanced non-small cell lung cancer. Lung Cancer.
67:348–354. 2010.
|
|
21.
|
Wu JY, Shih JY, Yang CH, et al:
Second-line treatments after first-line gefitinib therapy in
advanced non-small cell lung cancer. Int J Cancer. 126:247–255.
2010.
|
|
22.
|
Li L, Wang H, Yang ES, et al: Erlotinib
attenuates homologous recombinational repair of chromosomal breaks
in human breast cancer cells. Cancer Res. 68:9141–9146. 2008.
|
|
23.
|
Bandyopadhyay D, Mandal M, Adam L, et al:
Physical interaction between epidermal growth factor receptor and
DNA-dependent protein kinase in mammalian cells. J Biol Chem.
273:1568–1573. 1998.
|
|
24.
|
Rosell R, Perez-Roca L, Sanchez JJ, et al:
Customized treatment in non-small cell lung cancer based on EGFR
mutations and BRCA1 mRNA expression. PLoS One. 4:e51332009.
|
|
25.
|
Rosell R, Tarón M and O’Brate A:
Predictive molecular markers in non-small cell lung cancer. Curr
Opin Oncol. 13:101–109. 2001.
|
|
26.
|
Taron M, Rosell R, Felip E, et al: BRCA1
mRNA expression levels as an indicator of chemoresistance in lung
cancer. Hum Mol Genet. 13:2443–2449. 2004.
|
